Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions

Patent metadata

Field	Value
Publication number	US-2016151318-A1
Application number	US-201514921788-A
Country	US
Kind code	A1
Filing date	Oct 23, 2015
Priority date	Apr 18, 2008
Publication date	Jun 2, 2016
Grant date	—

Abstract

The present invention relates to methods of treating lipid disorders, lipid-related disorders or conditions, obesity and obesity-related disorders using nitrated lipids. In particular, the methods comprise administering effective amounts of nitrated fatty acids or esters thereof in order to reduce one or more of triglycerides, free fatty acids, body weight, cholesterol, urine protein excretion and oxidative stress or increase the level of plasma HDL in a subject.

First claim

What is claimed is:

1 . A method comprising administering a nitrated lipid to a subject in need thereof, in an amount effective to treat one or more of lipid disorders, obesity, lipid-related conditions or disorders, or obesity-related conditions or disorders.

2 . The method of claim 1 , wherein the lipid disorder is selected from one or more of hypertriglyceridemia, high free fatty acid concentration, and low high-density-lipoprotein-cholesterol concentration (hypo-HDL-C).

3 . The method of claim 2 , wherein the lipid disorder is associated with obesity.

4 . The method of claim 1 , wherein the lipid-related conditions or disorders and obesity-related conditions or disorders are selected from lipid- or obesity-related organ injuries or dysfunction, proteinuria, retinopathy, neuropathy, or nephropathy.

5 . The method of claim 1 , comprising administering a nitrated lipid to a subject in need thereof, in an amount effective to reduce the level of one or more of triglycerides, free fatty acids, body weight, cholesterol, urine protein excretion and oxidative stress or increase the level of plasma HDL in a subject relative to the subject's level or rate prior to the administration of the nitrated lipid.

6 . The method of claim 1 , wherein the nitrated lipid is administered in combination with one or more therapeutic agents, wherein the therapeutic agent is selected from agents useful in the treatment of lipid disorders, obesity, lipid-related conditions or disorders and obesity-related conditions or disorders.

7 . The method of claim 1 , wherein the nitrated lipid comprises a monounsaturated fatty acid or a polyunsaturated fatty acid.

8 . The method of claim 7 , wherein the monounsaturated fatty acid is oleic acid.

9 . The method of claim 8 , wherein the monosaturated fatty acid is selected from 9-nitrooleic acid, 10-nitrooleic acid, or combinations thereof.

10 . The method of claim 1 , wherein the amount ranges from about 1 μg to 1 g per day.

11 . The method of claim 5 , comprising administering a nitrated lipid to a subject in need thereof, in an amount effective to reduce the body weight of the subject, relative to the subject's body weight prior to administration of the nitrated lipid.

12 . The method of claim 11 , wherein the body weight is reduced from by about 5% to by about 15%.

13 . The method of claim 5 comprising administering a nitrated lipid to a subject in need thereof, in an amount effective to reduce the level of triglycerides in the subject, relative to the subject's level prior to the administration of the nitrated lipid.

14 . The method of claim 12 , wherein the level of triglycerides is reduced from by about 10% to by about 50%.

15 . The method of claim 5 comprising administering a nitrated lipid to a subject in need thereof, in an amount effective to reduce the level of free fatty acid in the subject, relative to the subject's level prior to the administration of the nitrated lipid

16 . The method of claim 15 , wherein the level of plasma free fatty acid is reduced by from by about 10% to about 90%.

17 . The method of claim 5 comprising administering a nitrated lipid to a subject in need thereof, in an amount effective to reduce the level of urine protein excretion in the subject, relative to the subject's level prior to the administration of the nitrated lipid

18 . The method of claim 17 , wherein the rate of urine protein excretion is reduced from by about 20% to about 70%.

19 . A method of claim 5 comprising administering a nitrated lipid to a subject in need thereof, in an amount effective to increase the level of plasma HDL in the subject, relative to the subject's level prior to the administration of the nitrated lipid.

20 . The method of claim 19 , wherein the level of plasma HDL is increased from by about 10% to about 90%.

21 . The method of claim 1 , wherein the subject is obese or morbidly obese.

Assignees

• Univ Utah Res Found

Inventors

• Yang Tianxin

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K31/201 Primary

  having one or two double bonds, e.g. oleic, linoleic acids · CPC title